I hope FDA get some sort of notification on all these advances. Very impressive data flow and i still think this surface wound application might be faster to market assuming it has less risk being an external treatment. From what i have seen the requirement for treating bacteria in open wounds is massive.
Ann: Further Positive Data on RECCE 327 Against MRSA Superbug, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.020(6.45%) |
Mkt cap ! $83.62M | |||
| Open | High | Low | Value | Volume |
| 30.5¢ | 30.5¢ | 28.5¢ | $106.1K | 361.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9988 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.5¢ | 24737 | 4 |
View Market Depth
| Last trade - 15.38pm 30/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |